MBX - MBX Biosciences, Inc. News

MBX Biosciences Announces First Patient Dosed In Pivotal Phase 3 oPTimize Clinical Trial Evaluating

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durableone-year

MBX Biosciences Announces First Patient Dosed in Pivotal Phase 3 oPTimize Trial of Once-Weekly Canvu

Pivotal Phase 3 oPTimize trial design builds on positive Phase 2 Avail™ results and durable one-year

JP Morgan Reinstates Overweight on MBX Biosciences, Announces $88 Price Target

JP Morgan analyst Jessica Fye reinstates MBX Biosciences (NASDAQ:MBX) with a Overweight and annou

accessnewswire.com

Microbix Reports Results for Q3 Fiscal 2026

Q3 Revenues of $4.1 million and Controlled Net Loss MISSISSAUGA, ON / ACCESS Newswire / August 13, 2

Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $88

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy

MBX Biosciences Q2 EPS $(0.78) Misses $(0.63) Estimate

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.78) per share which missed the analyst

defenseworld.net

MBX Biosciences (NASDAQ:MBX) Reaches New 12-Month High After Analyst Upgrade

MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report) shares hit a new 52-week high during mid-day t

Mizuho Maintains Outperform on MBX Biosciences, Raises Price Target to $91

Mizuho analyst Uy Ear maintains MBX Biosciences (NASDAQ:MBX) with a Outperform and raises the pri

defenseworld.net

MBX Biosciences (NASDAQ:MBX) Hits New 12-Month High – Here’s Why

MBX Biosciences, Inc. (NASDAQ: MBX - Get Free Report)'s share price hit a new 52-week high during tr

ManpowerGroup Posts Upbeat Q2 Earnings, Joins Docebo, Zentalis Pharmaceuticals And Other Big Stocks

US stocks lower, Nasdaq falls 400 pts. ManpowerGroup shares rise after upbeat earnings. Other big ga

defenseworld.net

Lakewood-Amedex Biotherapeutics (NASDAQ:LABT) vs. MBX Biosciences (NASDAQ:MBX) Critical Survey

MBX Biosciences (NASDAQ: MBX - Get Free Report) and Lakewood-Amedex Biotherapeutics (NASDAQ: LABT -

12 Health Care Stocks Moving In Monday's After-Market Session

Gainers Shuttle Pharmaceuticals (NASDAQ:SHPH) shares rose 56.1% to $4.62 during Monday's after-

MBX Biosciences Appoints Steve Hoerter As Chairman And CEO, Succeeding Kent Hawryluk, With John Smit

MBX Biosciences, Inc. (NASDAQ:MBX), a clinical-stage biopharmaceutical company focused on the discov

MBX Biosciences Announces Executive Leadership Transition to Support the Company's Next Phase of Gro

CARMEL, Ind. and BURLINGTON, Mass., July 13, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq:

MBX Biosciences: Weekly PTH, Monthly Obesity, Multi-Year Upside (Initiating Buy)

I initiate MBX Biosciences with a speculative buy, anchored by Canvuparatide's de-risked clinical pr

MBX Biosciences, Inc. (MBX) Discusses One-Year Data From Phase II Open-Label Extension Study of Once

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

MBX Biosciences Inc. (NASDAQ:MBX) on Thursday reported full results from its 12-week Avail Phase 2 t

MBX Biosciences Highlights Sustained Calcium Control In Rare Disease

MBX Biosciences reported one-year canvuparatide data showing sustained calcium control and progress

12 Health Care Stocks Moving In Friday's Pre-Market Session

Lennar Reports Mixed Q2 Results, Joins Adobe And Other Big Stocks Moving Lower In Friday's Pre-Marke

US stock futures rise, Dow futures up 300 points. Lennar Corp falls after reporting mixed Q2 results

MBX Biosciences Announces Full Results From 12-Week Avail Phase 2 Trial And New 1-Yr Data From Ongoi

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

MBX Biosciences Announces One-Year Data Demonstrating Sustained Benefit of Once-Weekly Canvuparatide

Responder rate of 57% at one year in open-label extension (OLE) comparable to 63% at 12 weeks in Pha

MBX Biosciences to Host Virtual Investor Event to Discuss Once-Weekly Canvuparatide Presentations at

CARMEL, Ind., June 01, 2026 (GLOBE NEWSWIRE) -- MBX Biosciences, Inc. (Nasdaq: MBX), a clinical-stag

fool.com

Chief Medical Officer Sells MBX for $2.7 Million After Monster 2026 Run

MBX Biosciences, a clinical-stage biotech developing peptide therapies, reported a notable insider s

MBX Biosciences to Present at the Jefferies 2026 Global Healthcare Conference in New York City

CARMEL, Ind. and BURLINGTON, Mass.

Microbix Biosystems Inc. (MBX:CA) Q2 2026 Earnings Call Transcript

Earnings Scheduled For May 14, 2026

Barclays Maintains Overweight on MBX Biosciences, Raises Price Target to $70

Barclays analyst Eliana Merle maintains MBX Biosciences (NASDAQ:MBX) with a Overweight and raises

Citizens Maintains Market Outperform on MBX Biosciences, Raises Price Target to $86

Citizens analyst Jonathan Wolleben maintains MBX Biosciences (NASDAQ:MBX) with a Market Outperfor

MBX Biosciences, Inc. (MBX) Discusses Novel Approaches and Clinical Progress in Obesity Therapeutics

marketbeat.com

MBX Biosciences Obesity Day Spotlights Monthly GLP-1 Hope and Pipeline Push

MBX Biosciences NASDAQ: MBX used its Obesity Day event to outline preliminary clinical data for its

Truist Securities Maintains Buy on MBX Biosciences, Raises Price Target to $70

Truist Securities analyst Srikripa Devarakonda maintains MBX Biosciences (NASDAQ:MBX) with a Buy

MBX Biosciences Announces Multiple Updates On Obesity Portfolio; Preliminary Blinded Phase 1 Data Fo

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%

MBX Biosciences Provides Obesity Portfolio Update Including Initial Phase 1 Data for MBX 4291 Suppor

Preliminary blinded data from ongoing Phase 1 trial demonstrated mean weight loss of 7% (range 0-16%

MBX Biosciences Q1 EPS $(0.51) Beats $(0.61) Estimate

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.51) per share which beat the analyst c

MBX Biosciences Reports First Quarter 2026 Financial Results and Corporate Highlights

Results from Phase 2 trial of once-weekly canvuparatide accepted for oral presentation at ENDO in Ju

accessnewswire.com

Microbix Schedules Release of Results for Q2 Fiscal 2026

Results Release and Webinar Discussion on Morning of May 14, 2026 MISSISSAUGA, ON / ACCESS Newswire

MBX Biosciences Announces Appointment of Mark Soued as Chief Commercial Officer and Inducement Grant

CARMEL, Ind. and BURLINGTON, Mass.

MBX Biosciences Q4 EPS $(0.49) Beats $(0.68) Estimate

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.49) per share which beat the analyst c

Earnings Scheduled For February 12, 2026

Barclays Initiates Coverage On MBX Biosciences with Overweight Rating, Announces Price Target of $66

Barclays analyst Eliana Merle initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Overweigh

Guggenheim Maintains Buy on MBX Biosciences, Raises Price Target to $88

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises

UBS Initiates Coverage On MBX Biosciences with Buy Rating, Announces Price Target of $60

UBS analyst Michael Yee initiates coverage on MBX Biosciences (NASDAQ:MBX) with a Buy rating and

Monte Rosa Therapeutics, Ventyx Biosciences, United Microelectronics And Other Big Stocks Moving Hig

Stifel Maintains Buy on MBX Biosciences, Raises Price Target to $50

Stifel analyst Annabel Samimy maintains MBX Biosciences (NASDAQ:MBX) with a Buy and raises the pr

Earnings Scheduled For December 18, 2025

Goldman Sachs Initiates Coverage On MBX Biosciences with Sell Rating, Announces Price Target of $18

Goldman Sachs analyst Corinne Johnson initiates coverage on MBX Biosciences (NASDAQ:MBX) with a S

Guggenheim Maintains Buy on MBX Biosciences, Lowers Price Target to $77

Guggenheim analyst Seamus Fernandez maintains MBX Biosciences (NASDAQ:MBX) with a Buy and lowers

MBX Biosciences Q3 EPS $(0.63) Beats $(0.70) Estimate

MBX Biosciences (NASDAQ:MBX) reported quarterly losses of $(0.63) per share which beat the analyst c